While sales for Darzalex were a tad below estimates, total revenue exceeded expectations in FY18 on the back of higher milestone income. Robust revenue acceleration is anticipated for FY19 as well, though operating profit would continue to be weighed down by higher investments into R&D. Given that the multi-blockbuster potential of Darzalex is still intact, we reiterate our ‘Buy’ recommendation.
22 Feb 2019
Darzalex to reach triple blockbuster in FY19; R&D investments set to continue
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Darzalex to reach triple blockbuster in FY19; R&D investments set to continue
Genmab A/S (GMAB:WBO) | 0 0 1.3% | Mkt Cap: 66,508m
- Published:
22 Feb 2019 -
Author:
Sumit Sayal -
Pages:
4
While sales for Darzalex were a tad below estimates, total revenue exceeded expectations in FY18 on the back of higher milestone income. Robust revenue acceleration is anticipated for FY19 as well, though operating profit would continue to be weighed down by higher investments into R&D. Given that the multi-blockbuster potential of Darzalex is still intact, we reiterate our ‘Buy’ recommendation.